Cancer II

This book reviews recent breakthroughs in anti-cancer drug discovery. Building on the previous volume in the series, it outlines some of the most significant developments that have occurred in the field in the subsequent period that have led to new drug approvals or promising clinical candidates. The volume is divided into chapters that each relate to a specific protein or protein class. Each chapter provides an overview of the underlying biology and then emphasises the medicinal chemistry strategies and tactics that led to the most significant drugs and drug candidates. A summary of clinical data and the future outlook for the field is also provided. Each chapter is authored by experts in the topic and who have themselves made significant contributions to their respective fields.

Zusammenfassung

This book reviews recent breakthroughs in anti-cancer drug discovery. Building on the previous volume in the series, it outlines some of the most significant developments that have occurred in the field in the subsequent period that have led to new drug approvals or promising clinical candidates. The volume is divided into chapters that each relate to a specific protein or protein class. Each chapter provides an overview of the underlying biology and then emphasises the medicinal chemistry strategies and tactics that led to the most significant drugs and drug candidates. A summary of clinical data and the future outlook for the field is also provided. Each chapter is authored by experts in the topic and who have themselves made significant contributions to their respective fields.

Inhalt
Progress in the Discovery of BCR-ABL Kinase Inhibitors for the Treatment of Leukemia.- Small Molecule Inhibitors of the Epidermal Growth Factor Receptor.- Small-Molecule Inhibitors of Bruton's Tyrosine Kinase.- Inhibitors of Vascular Endothelial Growth Factor Receptor.- Inhibitors of the Fibroblast Growth Factor Receptor.- Modulation of the DNA-Damage Response by Inhibitors of the Phosphatidylinositol 3-Kinase Related Kinase (PIKK) Family.- Epigenetic Modulators.- AntibodyDrug Conjugates.- Isoform Selective PI3K Inhibitors for Treating Cancer.- Inhibitors of the Kynurenine Pathway.- ProteinProtein Interaction Inhibitors.- Small Molecule Inhibitors of ALK.